Ponatinib Evaluation And safety in Real Life CML patients failing ≥2 tyrosine kinase inhibitors: The PEARL observational study.

Date publication

septembre 2018

Journal

Experimental hematology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GUERCI-BRESLER Agnès , Dr AME Shanti , Dr CHRETIEN Marie-Lorraine

Tous les auteurs :
Heiblig M, Rea D, Chrétien ML, Charbonnier A, Rousselot P, Coiteux V, Escoffre-Barbe M, Dubruille V, Huguet F, Cayssials E, Hermet E, Guerci-Bresler A, Amé S, Sackmann-Sala L, Roy L, Sobh M, Morisset S, Etienne G, Nicolini FE

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30195076

Résumé

Ponatinib represents a remarkable progress in the treatment of heavily pretreated CML and de novo Ph ALL patients despite significant toxicity in clinical trials. To date, "real-life" data remain few and the use of Ponatinib in this setting and its consequences remain mostly unknown.

Mots clés

Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, adverse effects, Cardiovascular Diseases, chemically induced, Compassionate Use Trials, Drug Resistance, Neoplasm, Female, Genes, abl, Humans, Imidazoles, adverse effects, Intention to Treat Analysis, Kaplan-Meier Estimate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, Male, Middle Aged, Patient Selection, Pragmatic Clinical Trials as Topic, Protein Kinase Inhibitors, adverse effects, Pyridazines, adverse effects, Salvage Therapy, Survival Analysis, Treatment Failure, Young Adult

Référence

Exp. Hematol.. 2018 Sep 5;: